Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medicinal cannabis company Bod Australia (BDA) has reported its Project Twenty21 patients have received their first medicinal cannabis prescriptions
  • Project Twenty21 is Europe’s largest medicinal cannabis registry, targeting 20,000 patients suffering from conditions such as chronic pain, multiple sclerosis and more
  • Bod is expecting to supply a minimum of 1000 patients during the registry with its unique five per cent MediCabilis cannabidiol product
  • The registry is expected to finish at the end of 2021, however, it may continue into 2022 due to the current market conditions
  • Bod is up 12.1 per cent on the market this afternoon, selling shares for 32.5 cents each

Medicinal cannabis company Bod Australia (BDA) has reported its Project Twenty21 patients have received their first medicinal cannabis prescriptions.

Project Twenty21 is Europes largest medicinal cannabis registry, targeting 20,000 patients suffering from conditions such as chronic pain, multiple sclerosis, post-traumatic stress, Tourette’s, anxiety and issues from substance abuse.

Bod is expecting to supply a minimum of 1000 patients during the registry with its unique five per cent MediCabilis cannabidiol product. MediCabilis will be sold for £150 per unit during Project Twenty21, which will add to Bod’s revenue.

The registry is expected to finish at the end of 2021, however, it may continue into 2022 due to the current market conditions.

Now that the registry has commenced, physicians and clinics across the U.K. can
prescribe Bod’s MediCabilis to patients participating in Project Twenty21.

“This is a major milestone for the company as it provides Bod with an additional sales channel for MediCabilis,” the company said.

CEO Jo Patterson said the commencement of Project Twenty21 is another opportunity to grow in a market estimated to be worth $3 billion by 2024.

“Participation in the registry opens another sales avenue for MediCabilis™ and will provide the company with exposure to a large number of physicians, patients and clinics across the country. This is pivotal as Bod continues to build brand awareness across the U.K.,” she said.

“We are confident that the U.K. will be an important growth market for MediCabilis and these initial patients provide the beginning of what will become a scalable revenue base for the company,” she added.

Bod is up 12.1 per cent on the market this afternoon, selling shares for 32.5 cents each at 1:01 pm AEST.

BDA by the numbers
More From The Market Herald
The Market Herald Video

" Imugene (ASX:IMU) sees “positive signs” from lung cancer trial, presents data at 2022 world conference

Imugene (ASX:IMU) presents new data from its PD1-Vaxx trial in non-small cell lung cancer patients at…

" Lumos Diagnostics (ASX:LDX) withdraws from RAT manufacturing facility project with VIC government

Lumos Diagnostics (ASX:LDX) has backed out of its deal with the Victorian Government to establish a…

" Creso Pharma’s (ASX:CPH) Mernova lands new purchase orders

Creso Pharma's (ASX:CPH) Canadian subsidiary, Mernova medicinal secured new purchase orders last month.
The Market Herald Video

" Neuren Pharmaceuticals (ASXL:NEU) launches phase two trials of NNZ-2591

Neuren Pharmaceuticals (ASX:NEU) opens enrolment for phase two clinical trials of its drug candidate NNZ-2591.